Aimed Alliance Urges CMS to Prioritize Transparency in IRA Negotiations
On June 26, 2025, Aimed Alliance submitted a comment to the Centers for Medicare & Medicaid Services (CMS) on its…
Browsing: Drug Pricing: Policy Activity
New Analysis Warns IRA Changes Could Raise Drug Costs for Most Medicare Beneficiaries
The Inflation Reduction Act (IRA) aimed to lower prescription drug costs by capping annual out-of-pocket spending for Medicare beneficiaries at…
Aimed Alliance Opposes Nevada’s MFP Bill
Aimed Alliance sent a letter to Governor Lombardo opposing Nevada Assembly Bill 259, which would cap health plan reimbursement for…
IRA Price Controls May Be Linked to Higher Out-of-Pocket Drug Costs
A new analysis from the Pioneer Institute shows that federal price controls under the Inflation Reduction Act (IRA) may be…
Oregon Senator Delays Bill Granting PDAB UPL Authority Amid Uncertainty
Oregon Senator Deb Patterson, Chair of the Senate Health Care Committee, has decided not to introduce a bill this session…
Youngkin Vetoes PDAB Bill in Virginia for Second Year
For the second consecutive year, Governor Glenn Youngkin has vetoed legislation aimed at establishing a Prescription Drug Affordability Board (PDAB).…
Aimed Alliance Asks Kansas to Consider Alternative to PDAB Legislation
Aimed Alliance submitted a letter to the Kansas Legislature, urging the Committee on Financial Institutions and Insurance to evaluate the…
Aimed Alliance Supports Creation of Rare Disease Council in Washington
Aimed Alliance provided a letter of support for the passage of Washington Senate Bill 5064, which would establish an advisory…
Aimed Alliance Comments on Maryland PDAB Draft Rules
Aimed Alliance provided feedback on Maryland’s Prescription Drug Affordability Board’s draft regulations, COMAR 14.01.0 and COMAR 14.01.05, which amend and…
Aimed Alliance Urges Virginia to Reconsider PDAB Bill
On January 24, 2025, Aimed Alliance submitted a comment to the Virginia House Appropriations – Health and Human Resources Subcommittee,…